Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 226
Filter
1.
Int J Mol Sci ; 21(13)2020 Jun 30.
Article in English | MEDLINE | ID: mdl-32629812

ABSTRACT

The mesodiencephalic dopaminergic (mdDA) group of neurons comprises molecularly distinct subgroups, of which the substantia nigra (SN) and ventral tegmental area (VTA) are the best known, due to the selective degeneration of the SN during Parkinson's disease. However, although significant research has been conducted on the molecular build-up of these subsets, much is still unknown about how these subsets develop and which factors are involved in this process. In this review, we aim to describe the life of an mdDA neuron, from specification in the floor plate to differentiation into the different subsets. All mdDA neurons are born in the mesodiencephalic floor plate under the influence of both SHH-signaling, important for floor plate patterning, and WNT-signaling, involved in establishing the progenitor pool and the start of the specification of mdDA neurons. Furthermore, transcription factors, like Ngn2, Ascl1, Lmx1a, and En1, and epigenetic factors, like Ezh2, are important in the correct specification of dopamine (DA) progenitors. Later during development, mdDA neurons are further subdivided into different molecular subsets by, amongst others, Otx2, involved in the specification of subsets in the VTA, and En1, Pitx3, Lmx1a, and WNT-signaling, involved in the specification of subsets in the SN. Interestingly, factors involved in early specification in the floor plate can serve a dual function and can also be involved in subset specification. Besides the mdDA group of neurons, other systems in the embryo contain different subsets, like the immune system. Interestingly, many factors involved in the development of mdDA neurons are similarly involved in immune system development and vice versa. This indicates that similar mechanisms are used in the development of these systems, and that knowledge about the development of the immune system may hold clues for the factors involved in the development of mdDA neurons, which may be used in culture protocols for cell replacement therapies.


Subject(s)
Dopaminergic Neurons/metabolism , Mesencephalon/cytology , Mesencephalon/embryology , Animals , Cell Differentiation/genetics , Dopamine/metabolism , Dopaminergic Neurons/physiology , Embryo, Mammalian/cytology , Gene Expression Regulation, Developmental/genetics , Humans , Mesencephalon/metabolism , Mesencephalon/physiology , Substantia Nigra/embryology , Substantia Nigra/metabolism , Transcription Factors/genetics , Ventral Tegmental Area/embryology , Ventral Tegmental Area/metabolism
2.
PLoS One ; 12(3): e0173978, 2017.
Article in English | MEDLINE | ID: mdl-28334019

ABSTRACT

Regenerative medicine requires, in many cases, physical supports to facilitate appropriate cellular architecture, cell polarization and the improvement of the correct differentiation processes of embryonic stem cells, induced pluripotent cells or adult cells. Because the interest in carbon nanomaterials has grown within the last decade in light of a wide variety of applications, the aim of this study was to test and evaluate the suitability and cytocompatibility of a particular nanometer-thin nanocrystalline glass-like carbon film (NGLC) composed of curved graphene flakes joined by an amorphous carbon matrix. This material is a disordered structure with high transparency and electrical conductivity. For this purpose, we used a cell line (SN4741) from substantia nigra dopaminergic cells derived from transgenic mouse embryos. Cells were cultured either in a powder of increasing concentrations of NGLC microflakes (82±37µm) in the medium or on top of nanometer-thin films bathed in the same culture medium. The metabolism activity of SN4741 cells in presence of NGLC was assessed using methylthiazolyldiphenyl-tetrazolium (MTT) and apoptosis/necrosis flow cytometry assay respectively. Growth and proliferation as well as senescence were demonstrated by western blot (WB) of proliferating cell nuclear antigen (PCNA), monoclonal phosphorylate Histone 3 (serine 10) (PH3) and SMP30 marker. Specific dopaminergic differentiation was confirmed by the WB analysis of tyrosine hydroxylase (TH). Cell maturation and neural capability were characterized using specific markers (SYP: synaptophysin and GIRK2: G-protein-regulated inward-rectifier potassium channel 2 protein) via immunofluorescence and coexistence measurements. The results demonstrated cell positive biocompatibility with different concentrations of NGLC. The cells underwent a process of adaptation of SN4741 cells to NGLC where their metabolism decreases. This process is related to a decrease of PH3 expression and significant increase SMP30 related to senescence processes. After 7 days, the cells increased the expression of TH and PCNA that is related to processes of DNA replication. On the other hand, cells cultured on top of the film showed axonal-like alignment, edge orientation, and network-like images after 7 days. Neuronal capability was demonstrated to a certain extent through the analysis of significant coexistence between SYP and GIRK2. Furthermore, we found a direct relationship between the thickness of the films and cell maturation. Although these findings share certain similarities to our previous findings with graphene oxide and its derivatives, this particular nanomaterial possesses the advantages of high conductivity and transparency. In conclusion, NGLC could represent a new platform for biomedical applications, such as for use in neural tissue engineering and biocompatible devices.


Subject(s)
Dopaminergic Neurons/cytology , Nanoparticles , Substantia Nigra/cytology , Tissue Scaffolds , Animals , Biofilms , Blotting, Western , Cell Differentiation , Cell Line , Cell Survival , Dopaminergic Neurons/physiology , Mice , Mice, Transgenic , Microscopy/methods , Substantia Nigra/embryology , Substantia Nigra/physiology
3.
Neuroscience ; 314: 134-44, 2016 Feb 09.
Article in English | MEDLINE | ID: mdl-26642808

ABSTRACT

Fibroblast growth factors (FGFs) regulate development and maintenance, and reduce vulnerability of neurons. FGF-2 is essential for survival of midbrain dopaminergic (DA) neurons and is responsible for their dysplasia and disease-related degeneration. We previously reported that FGF-2 is involved in adequate forebrain (FB) target innervation by these neurons in an organotypic co-culture model. It remains unclear, how this ex-vivo phenotype relates to the in vivo situation, and which FGF-related signaling pathway is involved in this process. Here, we demonstrate that lack of FGF-2 results in an increased volume of the striatal target area in mice. We further add evidence that the low molecular weight (LMW) FGF-2 isoform is responsible for this phenotype, as this isoform is predominantly expressed in the embryonic ventral midbrain (VM) as well as in postnatal striatum (STR) and known to act via canonical transmembrane FGF receptor (FGFR) activation. Additionally, we confirm that the phenotype with an enlarged FB-target area by DA neurons can be mimicked in an ex-vivo explant model by inhibiting the canonical FGFR signaling, which resulted in decreased extracellular signal-regulated kinase (ERK) activation, while AKT activation remained unchanged.


Subject(s)
Corpus Striatum/cytology , Corpus Striatum/metabolism , Dopaminergic Neurons/cytology , Fibroblast Growth Factor 2/physiology , Substantia Nigra/cytology , Substantia Nigra/metabolism , Animals , Corpus Striatum/embryology , Dopaminergic Neurons/metabolism , Fibroblast Growth Factor 2/genetics , Fibroblast Growth Factor 2/metabolism , MAP Kinase Signaling System , Mice , Mice, Inbred C57BL , Mice, Knockout , Neural Pathways/cytology , Neural Pathways/embryology , Neural Pathways/metabolism , Prosencephalon , Protein Isoforms/physiology , Proto-Oncogene Proteins c-akt/metabolism , Receptor, Fibroblast Growth Factor, Type 1/metabolism , Substantia Nigra/embryology , Tyrosine 3-Monooxygenase/metabolism
4.
J Neurosci ; 35(43): 14467-75, 2015 Oct 28.
Article in English | MEDLINE | ID: mdl-26511239

ABSTRACT

The mammalian striatum controls sensorimotor and psychoaffective functions through coordinated activities of its two striatonigral and striatopallidal output pathways. Here we show that retinoic acid receptor ß (RARß) controls development of a subpopulation of GABAergic, Gad65-positive striatonigral projection neurons. In Rarb(-/-) knock-out mice, concomitant reduction of Gad65, dopamine receptor D1 (Drd1), and substance P expression at different phases of prenatal development was associated with reduced number of Drd1-positive cells at birth, in contrast to normal numbers of striatopallidal projection neurons expressing dopamine receptor D2. Fate mapping using BrdU pulse-chase experiments revealed that such deficits may originate from compromised proliferation of late-born striosomal neurons and lead to decreased number of Drd1-positive cells retaining BrdU in postnatal day (P) 0 Rarb(-/-) striatum. Reduced expression of Fgf3 in the subventricular zone of the lateral ganglionic eminence (LGE) at embryonic day 13.5 may underlie such deficits by inducing premature differentiation of neuronal progenitors, as illustrated by reduced expression of the proneural gene Ascl1 (Mash1) and increased expression of Meis1, a marker of postmitotic LGE neurons. In agreement with a critical role of FGF3 in this control, reduced number of Ascl1-expressing neural progenitors, and a concomitant increase of Meis1-expressing cells, were observed in primary cell cultures of Rarb(-/-) LGE. This defect was normalized by addition of fibroblast growth factor (FGF). Such data point to role of Meis1 in striatal development, also supported by reduced neuronal differentiation in the LGE of Meis1(-/-) embryos. Our data unveil a novel mechanism of development of striatonigral projection neurons involving retinoic acid and FGF, two signals required for positioning the boundaries of Meis1-expressing cells.


Subject(s)
Corpus Striatum/physiology , Fibroblast Growth Factors/physiology , Homeodomain Proteins/physiology , Neoplasm Proteins/physiology , Neurons/physiology , Receptors, Retinoic Acid/physiology , Substantia Nigra/physiology , Animals , Antimetabolites/pharmacology , Bromodeoxyuridine/pharmacology , Corpus Striatum/cytology , Corpus Striatum/embryology , Female , Fibroblast Growth Factor 3/metabolism , Glutamate Decarboxylase/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Myeloid Ecotropic Viral Integration Site 1 Protein , Neurogenesis/genetics , Neurogenesis/physiology , Pregnancy , Primary Cell Culture , Receptors, Dopamine D1/metabolism , Substantia Nigra/cytology , Substantia Nigra/embryology
5.
Cell Rep ; 8(4): 1018-25, 2014 Aug 21.
Article in English | MEDLINE | ID: mdl-25127144

ABSTRACT

Distinct midbrain dopamine (mDA) neuron subtypes are found in the substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA), but it is mainly SNc neurons that degenerate in Parkinson's disease. Interest in how mDA neurons develop has been stimulated by the potential use of stem cells in therapy or disease modeling. However, very little is known about how specific dopaminergic subtypes are generated. Here, we show that the expression profiles of the transcription factors Sox6, Otx2, and Nolz1 define subpopulations of mDA neurons already at the neural progenitor cell stage. After cell-cycle exit, Sox6 selectively localizes to SNc neurons, while Otx2 and Nolz1 are expressed in a subset of VTA neurons. Importantly, Sox6 ablation leads to decreased expression of SNc markers and a corresponding increase in VTA markers, while Otx2 ablation has the opposite effect. Moreover, deletion of Sox6 affects striatal innervation and dopamine levels. We also find reduced Sox6 levels in Parkinson's disease patients. These findings identify Sox6 as a determinant of SNc neuron development and should facilitate the engineering of relevant mDA neurons for cell therapy and disease modeling.


Subject(s)
Dopaminergic Neurons/physiology , Otx Transcription Factors/physiology , SOXD Transcription Factors/physiology , Substantia Nigra/cytology , Ventral Tegmental Area/cytology , Animals , Body Patterning , Humans , Mice, Transgenic , Organ Specificity , Substantia Nigra/embryology , Substantia Nigra/metabolism , Ventral Tegmental Area/embryology , Ventral Tegmental Area/metabolism
6.
Neuromolecular Med ; 16(2): 473-89, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24682653

ABSTRACT

Ventral midbrain (VM) dopaminergic (DA) neurons project to the dorsal striatum via the nigrostriatal pathway to regulate voluntary movements, and their loss leads to the motor dysfunction seen in Parkinson's disease (PD). Despite recent progress in the understanding of VM DA neurogenesis, the factors regulating nigrostriatal pathway development remain largely unknown. The bone morphogenetic protein (BMP) family regulates neurite growth in the developing nervous system and may contribute to nigrostriatal pathway development. Two related members of this family, BMP2 and growth differentiation factor (GDF)5, have neurotrophic effects, including promotion of neurite growth, on cultured VM DA neurons. However, the molecular mechanisms regulating their effects on DA neurons are unknown. By characterising the temporal expression profiles of endogenous BMP receptors (BMPRs) in the developing and adult rat VM and striatum, this study identified BMP2 and GDF5 as potential regulators of nigrostriatal pathway development. Furthermore, through the use of noggin, dorsomorphin and BMPR/Smad plasmids, this study demonstrated that GDF5- and BMP2-induced neurite outgrowth from cultured VM DA neurons is dependent on BMP type I receptor activation of the Smad 1/5/8 signalling pathway.


Subject(s)
Bone Morphogenetic Protein 2/physiology , Bone Morphogenetic Protein Receptors, Type I/physiology , Dopaminergic Neurons/physiology , Growth Differentiation Factor 5/physiology , Mesencephalon/cytology , Neurites/ultrastructure , Signal Transduction/physiology , Smad Proteins/physiology , Animals , Bone Morphogenetic Protein 2/antagonists & inhibitors , Bone Morphogenetic Protein 2/pharmacology , Bone Morphogenetic Protein Receptors, Type I/biosynthesis , Bone Morphogenetic Protein Receptors, Type I/genetics , Bone Morphogenetic Protein Receptors, Type II/biosynthesis , Bone Morphogenetic Protein Receptors, Type II/genetics , Bone Morphogenetic Protein Receptors, Type II/physiology , Carrier Proteins/genetics , Carrier Proteins/physiology , Cells, Cultured , Corpus Striatum/embryology , Corpus Striatum/growth & development , Dopaminergic Neurons/enzymology , Dopaminergic Neurons/ultrastructure , Female , Gene Expression Regulation, Developmental , Growth Differentiation Factor 5/antagonists & inhibitors , Mesencephalon/embryology , Mesencephalon/growth & development , Neurogenesis/physiology , Pyrazoles , Pyrimidines , Rats , Rats, Sprague-Dawley , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Substantia Nigra/embryology , Substantia Nigra/growth & development , Transfection , Tyrosine 3-Monooxygenase/biosynthesis
7.
PLoS One ; 8(10): e76037, 2013.
Article in English | MEDLINE | ID: mdl-24116087

ABSTRACT

The development of mesodiencephalic dopaminergic (mdDA) neurons located in the substantia nigra compacta (SNc) and ventral tegmental area (VTA) follow a number of stages marked by distinct events. After preparation of the region by signals that provide induction and patterning, several transcription factors have been identified, which are involved in specifying the neuronal fate of these cells. The specific vulnerability of SNc neurons is thought to root in these specific developmental programs. The present study examines the positions of young postmitotic mdDA neurons to relate developmental position to mdDA subset specific markers. MdDA neurons were mapped relative to the neuromeric domains (prosomeres 1-3 (P1-3), midbrain, and hindbrain) as well as the longitudinal subdivisions (floor plate, basal plate, alar plate), as proposed by the prosomeric model. We found that postmitotic mdDA neurons are located mainly in the floorplate domain and very few in slightly more lateral domains. Moreover, mdDA neurons are present along a large proportion of the anterior/posterior axis extending from the midbrain to P3 in the diencephalon. The specific positions relate to some extent to the presence of specific subset markers as Ahd2. In the adult stage more of such subsets specific expressed genes are present and may represent a molecular map defining molecularly distinct groups of mdDA neurons.


Subject(s)
Dopaminergic Neurons/metabolism , Gene Expression Regulation, Developmental , Substantia Nigra/metabolism , Ventral Tegmental Area/metabolism , Animals , Dopaminergic Neurons/cytology , Mice , Substantia Nigra/cytology , Substantia Nigra/embryology , Ventral Tegmental Area/cytology , Ventral Tegmental Area/embryology
8.
Proc Natl Acad Sci U S A ; 110(42): E4026-35, 2013 Oct 15.
Article in English | MEDLINE | ID: mdl-24082127

ABSTRACT

The mammalian striatum controls the output of the basal ganglia via two distinct efferent pathways, the direct (i.e., striatonigral) and the indirect (i.e., striatopallidal) pathways. The LIM homeodomain transcription factor Islet1 (Isl1) is expressed in a subpopulation of striatal progenitors; however, its specific role in striatal development remains unknown. Our genetic fate-mapping results show that Isl1-expressing progenitors give rise to striatal neurons belonging to the striatonigral pathway. Conditional inactivation of Isl1 in the telencephalon resulted in a smaller striatum with fewer striatonigral neurons and reduced projections to the substantia nigra. Additionally, conditional inactivation in the ventral forebrain (including both the telencephalon and diencephalon) revealed a unique role for Isl1 in diencephalic cells bordering the internal capsule for the normal development of the striatonigral pathway involving PlexinD1-Semaphorin 3e (Sema3e) signaling. Finally, Isl1 conditional mutants displayed a hyperlocomotion phenotype, and their locomotor response to psychostimulants was significantly blunted, indicating that the alterations in basal ganglia circuitry contribute to these mutant behaviors.


Subject(s)
Corpus Striatum/embryology , LIM-Homeodomain Proteins/metabolism , Nerve Tissue Proteins/metabolism , Signal Transduction/physiology , Substantia Nigra/embryology , Transcription Factors/metabolism , Animals , Behavior, Animal/physiology , Cell Adhesion Molecules, Neuronal/genetics , Cell Adhesion Molecules, Neuronal/metabolism , Corpus Striatum/cytology , Cytoskeletal Proteins , Glycoproteins/genetics , Glycoproteins/metabolism , Intracellular Signaling Peptides and Proteins , LIM-Homeodomain Proteins/genetics , Membrane Glycoproteins , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice , Mice, Knockout , Nerve Tissue Proteins/genetics , Semaphorins , Substantia Nigra/cytology , Transcription Factors/genetics
9.
Neurosci Lett ; 553: 142-7, 2013 Oct 11.
Article in English | MEDLINE | ID: mdl-23994060

ABSTRACT

Oxygen tension is critical for proliferation of human and murine midbrain-derived neural precursor cells (mNPCs). Lack of hypoxia-inducible factor-1α (HIF1α) impairs midbrain dopaminergic neurogenesis which could be rescued by vascular endothelial growth factor (VEGF) via VEGFR-2 signaling. Here, we conditionally inactivated the VEGFR-2, encoded by the fetal liver kinase 1 (Flk1) gene, in murine NPCs to determine its role in proliferation and survival in vitro as well as survival of dopaminergic neurons in vivo. Flk1 conditional knock-out (Flk1 CKO) mice showed no general brain phenotype. There was no midbrain-specific impairment of NPC proliferation as seen in HIF1α CKO mice. In the substantia nigra (SN) of adult Flk1 CKO mice, nonbiased stereological cell counts revealed no reduction of TH-positive neurons of Flk1 CKO mice compared with control Cre/wt mice (in which the wild-type Flk1 allele is expressed in parallel with the Cre recombinase allele). In conclusion, VEGF receptor signaling seems not to be relevant to the development and survival of substantia nigra dopaminergic neurons within the hypoxia-HIF1α signaling pathway.


Subject(s)
Substantia Nigra/metabolism , Vascular Endothelial Growth Factor Receptor-2/metabolism , Animals , Cell Survival , Dopaminergic Neurons/cytology , Mice , Mice, Transgenic , Neurogenesis , Signal Transduction , Substantia Nigra/embryology , Substantia Nigra/growth & development , Vascular Endothelial Growth Factor Receptor-2/genetics
10.
Eur J Neurosci ; 37(10): 1564-72, 2013 May.
Article in English | MEDLINE | ID: mdl-23489835

ABSTRACT

Mouse models with prenatal alterations in dopaminergic functioning can provide new opportunities to identify fetal behavioral abnormalities and the underlying neural substrates dependent on dopamine. In this study, we tested the hypothesis that prenatal loss of nigrostriatal function is associated with fetal akinesia, or difficulty initiating movement. Specific behaviors were analysed in fetal offspring derived from pregnant Pitx3(ak) /2J and C57BL/6J dams on the last 4 days before birth (E15-18 of a 19-day gestation). Using digital videography, we analysed: (i) behavioral state, by quantification of high- and low-amplitude movements, (ii) interlimb movement synchrony, a measure of the temporal relationship between spontaneous movements of limb pairs, (iii) facial wiping, a characteristic response to perioral tactile stimulation similar to the defensive response in human infants, and (iv) oral grasp of a non-nutritive nipple, a component of suckling in the human infant. Pitx3 mutants showed a selective decrease in interlimb movement synchrony rates at the shortest (0.1 s) temporal interval coupled with significantly increased latencies to exhibit facial wiping and oral grasp. Collectively, our findings provide evidence that the primary fetal neurobehavioral deficit of the Pitx3 mutation is akinesia related to nigrostriatal damage. Other findings of particular interest were the differences in neurobehavioral functioning between C57BL/6J and Pitx3 heterozygous subjects, suggesting the two groups are not equivalent controls. These results further suggest that fetal neurobehavioral assessments are sensitive indicators of emerging neural dysfunction, and may have utility for prenatal diagnosis.


Subject(s)
Dopamine/metabolism , Fetal Movement/genetics , Homeodomain Proteins/genetics , Phenotype , Transcription Factors/genetics , Animals , Heterozygote , Mice , Mice, Inbred C57BL , Substantia Nigra/embryology , Substantia Nigra/physiology
11.
J Child Neurol ; 28(1): 60-9, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22532552

ABSTRACT

Synaptogenesis can be detected in tissue sections by immunoreactivity for synaptophysin, a synaptic vesicle glycoprotein that serves as a marker of synaptic maturation. Reactivity was prospectively studied postmortem in sections of the striatum, globus pallidus, and substantia nigra in 172 normal human fetuses and neonates of 6 to 41 weeks' gestation. Caudate nucleus and putamen show patchy reactivity beginning at 13 weeks' gestation around some intracapsular neurons; the pattern is well developed in all regions before midgestation. Near-uniform reactivity throughout the striatum is achieved by 34 weeks, but subtle patchiness is still perceived at term. The globus pallidus shows uniform reactivity without stria from 13 weeks and the substantia nigra from 9 weeks. Synaptic patchiness in the fetal corpus striatum appears to correspond to the "striosomes of Graybiel" that define adjacent neurotransmitter-rich and neurotransmitter-poor zones. Clinical correlation is proposed with dystonic postures and athetoid movements observed in normal preterm neonates of 26 to 32 weeks.


Subject(s)
Corpus Striatum , Globus Pallidus , Substantia Nigra , Synapses/physiology , Age Factors , Corpus Striatum/cytology , Corpus Striatum/embryology , Corpus Striatum/growth & development , Female , Fetus , Gestational Age , Globus Pallidus/cytology , Globus Pallidus/embryology , Globus Pallidus/growth & development , Humans , Infant , Infant, Newborn , Male , Postmortem Changes , Substantia Nigra/cytology , Substantia Nigra/embryology , Substantia Nigra/growth & development , Synapses/metabolism , Synaptophysin/metabolism
12.
PLoS One ; 7(11): e50178, 2012.
Article in English | MEDLINE | ID: mdl-23209667

ABSTRACT

Evidence from carefully conducted open label clinical trials suggested that therapeutic benefit can be achieved by grafting fetal dopaminergic (DAergic) neurons derived from ventral mesencephalon (VM) into the denervated striatum of Parkinson's disease (PD) patients. However, two double-blind trials generated negative results reporting deleterious side effects such as prominent dyskinesias. Heterogeneous composition of VM grafts is likely to account for suboptimal clinical efficacy.We consider that gene expression patterns of the VM tissue needs to be better understood by comparing the genetic signature of the surviving and functioning grafts with the cell suspensions used for transplantation. In addition, it is crucial to assess whether the grafted cells exhibit the DAergic phenotype of adult substantia nigra pars compacta (SNpc). To investigate this further, we used a GFP reporter mouse as source of VM tissue that enabled the detection and dissection of the grafts 6 weeks post implantation. A comparative gene expression analysis of the VM cell suspension and grafts revealed that VM grafts continue to differentiate post-implantation. In addition, implanted grafts showed a mature SNpc-like molecular DAergic phenotype with similar expression levels of TH, Vmat2 and Dat. However, by comparing gene expression of the adult SNpc with dissected grafts we detected a higher expression of progenitor markers in the grafts. Finally, when compared to the VM cell suspension, post-grafting there was a higher expression of markers inherent to glia and other neuronal populations.In summary, our data highlight the dynamic development of distinctive DAergic and non-DAergic gene expression markers associated with the maturation of VM grafts in vivo. The molecular signature of VM grafts and its functional relevance should be further explored in future studies aimed at the optimization of DAergic cell therapy approaches in PD.


Subject(s)
Mesencephalon/drug effects , Mesencephalon/embryology , Oxidopamine/pharmacology , Parkinson Disease/drug therapy , Adrenergic Agents/pharmacology , Amphetamines/pharmacology , Animals , Cell Transplantation/methods , Chickens , Dyskinesias/metabolism , Gene Expression Profiling , Gene Expression Regulation , Genes, Reporter , Genetic Markers , Green Fluorescent Proteins/metabolism , Humans , Mice , Mice, Inbred C57BL , Neuroglia/metabolism , Neurons/metabolism , Phenotype , Rats , Rats, Wistar , Stem Cells/cytology , Substantia Nigra/embryology , Substantia Nigra/metabolism , Time Factors
13.
Am J Psychiatry ; 169(12): 1301-8, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23212061

ABSTRACT

OBJECTIVE: The single-nucleotide polymorphism rs1344706, located within an intron of the ZNF804A gene, exhibits genome-wide significant association with schizophrenia. Although genotype at rs1344706 is associated with altered functional brain connectivity, the molecular mechanisms mediating its association with schizophrenia have not been clearly defined. Given its location in noncoding sequence, the authors tested association between rs1344706 and ZNF804A expression in adult and fetal human brain. METHOD: Highly quantitative measures of relative allelic expression were used to assess the effect of rs1344706 genotype on the mRNA expression of ZNF804A in the dorsolateral prefrontal cortex, hippocampus, and substantia nigra of the adult human brain and in human brain tissue from the first and second trimester of gestation. RESULTS: Genotype at rs1344706 had no significant effect on the regulation of ZNF804A in any of the three adult brain regions examined. In contrast, rs1344706 genotype had a significant effect on ZNF804A allelic expression in second-trimester fetal brain, with the schizophrenia risk (T) allele associated with reduced ZNF804A expression. CONCLUSIONS: The T allele of rs1344706 is associated with a relative decrease in ZNF804A expression during the second trimester of fetal brain development. These data provide evidence for a schizophrenia risk mechanism that is operational in (and possibly specific to) the fetal brain.


Subject(s)
Brain/embryology , Kruppel-Like Transcription Factors/genetics , Schizophrenia/genetics , Adult , Aged , Aged, 80 and over , Brain/metabolism , Brain/physiopathology , Female , Gene Expression/physiology , Genotype , Haplotypes , Hippocampus/embryology , Hippocampus/metabolism , Hippocampus/physiopathology , Humans , Kruppel-Like Transcription Factors/physiology , Linkage Disequilibrium , Middle Aged , Polymorphism, Single Nucleotide/genetics , Prefrontal Cortex/embryology , Prefrontal Cortex/metabolism , Prefrontal Cortex/physiopathology , Pregnancy , Pregnancy Trimester, First , Pregnancy Trimester, Second , Risk Factors , Schizophrenia/physiopathology , Substantia Nigra/embryology , Substantia Nigra/metabolism , Substantia Nigra/physiopathology , Young Adult
14.
Histol Histopathol ; 27(12): 1529-38, 2012 12.
Article in English | MEDLINE | ID: mdl-23059883

ABSTRACT

The midbrain is a complex structure where different functions are located. This formation is mainly involved in the visual and auditory information process (tectum) and visual movements and motor coordination (tegmentum). Here we display a complete description of midbrain anatomy based on the prosomeric model and of the developmental events that take place to generate this structure. We also summarize the new data about the differentiation and specification of the basal populations of the midbrain. The neural tube suffers the influence of several secondary organizers. These signaling centers confer exact positional information to the neuroblasts. In the midbrain these centers are the Isthmic organizer for the antero-posterior axis and the floor and roof plates for the dorso-ventral axis. This segment of the brain contains, in the dorsal part, structures such as the collicula (superior and inferior), tectal grey and the preisthmic segment, and in the basal plate, neuronal populations such as the oculomotor complex, the dopaminergic substantia nigra and the ventral tegmental area, the reticular formation and the periacueductal grey. Knowledge of the genetic cascades involved in the differentiation programs of the diverse populations will be extremely important to understand not only how the midbrain develops, but how degenerative pathologies, such as Parkinson's disease, occurs. These cascades are triggered by signaling molecules such as Shh, Fgf8 or Wnt1 and are integrated by receptor complexes and transcription factors. These are directly responsible for the induction or repression of the differentiation programs that will produce a specific neuronal phenotype.


Subject(s)
Mesencephalon/cytology , Neurons/cytology , Animals , Body Patterning/genetics , Body Patterning/physiology , Cell Differentiation , Fibroblast Growth Factor 8/metabolism , Gene Expression Regulation, Developmental , Mesencephalon/embryology , Mesencephalon/metabolism , Mice , Models, Neurological , Neurons/metabolism , Periaqueductal Gray/cytology , Periaqueductal Gray/embryology , Periaqueductal Gray/metabolism , Red Nucleus/cytology , Red Nucleus/embryology , Red Nucleus/metabolism , Reticular Formation/cytology , Reticular Formation/embryology , Reticular Formation/metabolism , Substantia Nigra/cytology , Substantia Nigra/embryology , Substantia Nigra/metabolism , Ventral Tegmental Area/cytology , Ventral Tegmental Area/embryology , Ventral Tegmental Area/metabolism
15.
Exp Neurol ; 236(1): 58-68, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22524988

ABSTRACT

Clinical trials have provided proof of principle that new dopamine neurons isolated from the developing ventral midbrain and transplanted into the denervated striatum can functionally integrate and alleviate symptoms in Parkinson's disease patients. However, extensive variability across patients has been observed, ranging from long-term motor improvement to the absence of symptomatic relief and development of dyskinesias. Heterogeneity of the donor tissue is likely to be a contributing factor in the variable outcomes. Dissections of ventral midbrain used for transplantation will variously contain progenitors for different dopamine neuron subtypes as well as different neurotransmitter phenotypes. The overall impact of the resulting graft will be determined by the functional contribution from these different cell types. The A9 substantia nigra pars compacta dopamine neurons, for example, are known to be particularly important for motor recovery in animal models. Serotonergic neurons, on the other hand, have been implicated in unwanted dyskinesias. Currently little knowledge exists on how variables such as donor age, which have not been controlled for in clinical trials, will impact on the final neuronal composition of fetal grafts. Here we performed a birth dating study to identify the time-course of neurogenesis within the various ventral midbrain dopamine subpopulations in an effort to identify A9-enriched donor tissue for transplantation. The results show that A9 neurons precede the birth of A10 ventral tegmental area dopamine neurons. Subsequent grafting of younger ventral midbrain donor tissue revealed significantly larger grafts containing more mitotic dopamine neuroblasts compared to older donor grafts. These grafts were enriched with A9 neurons and showed significantly greater innervation of the target dorso-lateral striatum and DA release. Younger donor grafts also contained significantly less serotonergic neurons. These findings demonstrate the importance of standardized methods to improve cell therapy for Parkinson's disease and have significant implications for the generation and selectivity of dopamine neurons from stem cell based sources.


Subject(s)
Brain Tissue Transplantation/methods , Dopaminergic Neurons/transplantation , Fetal Tissue Transplantation/methods , Parkinsonian Disorders/surgery , Substantia Nigra/transplantation , Animals , Brain Tissue Transplantation/pathology , Cell Differentiation/physiology , Disease Models, Animal , Dopaminergic Neurons/cytology , Dopaminergic Neurons/physiology , Female , Fetal Tissue Transplantation/pathology , Mice , Mice, Transgenic , Neurogenesis/physiology , Parkinsonian Disorders/pathology , Primary Cell Culture , Substantia Nigra/embryology , Substantia Nigra/physiology
16.
J Neurochem ; 122(1): 94-105, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22537018

ABSTRACT

Fibroblast growth factor 2 (FGF-2) is a neurotrophic factor participating in regulation of proliferation, differentiation, apoptosis and neuroprotection in the central nervous system. With regard to dopaminergic (DA) neurons of substantia nigra pars compacta (SNpc), which degenerate in Parkinson's disease, FGF-2 improves survival of mature DA neurons in vivo and regulates expansion of DA progenitors in vitro. To address the physiological role of FGF-2 in SNpc development, embryonic (E14.5), newborn (P0) and juvenile (P28) FGF-2-deficient mice were investigated. Stereological quantification of DA neurons identified normal numbers in the ventral tegmental area, whereas the SNpc of FGF-2-deficient mice displayed a 35% increase of DA neurons at P0 and P28, but not at earlier stage E14.5. Examination of DA marker gene expression by quantitative RT-PCR and in situ hybridization revealed a normal patterning of embryonic ventral mesencephalon. However, an increase of proliferating Lmx1a DA progenitors in the subventricular zone of the ventral mesencephalon of FGF-2-deficient embryos indicated altered cell cycle progression of neuronal progenitors. Increased levels of nuclear FgfR1 in E14.5 FGF-2-deficient mice suggest alterations of integrative nuclear FgfR1 signaling (INFS). In summary, FGF-2 restricts SNpc DA neurogenesis in vivo during late stages of embryonic development.


Subject(s)
Dopaminergic Neurons/physiology , Fibroblast Growth Factor 2/metabolism , Gene Expression Regulation, Developmental/genetics , Substantia Nigra/cytology , Ventral Tegmental Area/cytology , Age Factors , Animals , Animals, Newborn , Body Patterning/genetics , Bromodeoxyuridine , Cell Count , Cell Death/genetics , Embryo, Mammalian , Fibroblast Growth Factor 2/deficiency , LIM-Homeodomain Proteins/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Neurogenesis/genetics , Receptor, Fibroblast Growth Factor, Type 1/metabolism , Signal Transduction/genetics , Substantia Nigra/embryology , Substantia Nigra/growth & development , Transcription Factors/metabolism , Tyrosine 3-Monooxygenase/metabolism , Ventral Tegmental Area/embryology , Ventral Tegmental Area/growth & development
17.
J Neurosci ; 31(36): 12802-15, 2011 Sep 07.
Article in English | MEDLINE | ID: mdl-21900559

ABSTRACT

Pitx3 is a critical homeodomain transcription factor for the proper development and survival of mesodiencephalic dopaminergic (mdDA) neurons in mammals. Several variants of this gene have been associated with human Parkinson's disease (PD), and lack of Pitx3 in mice causes the preferential loss of substantia nigra pars compacta (SNc) mdDA neurons that are most affected in PD. It is currently unclear how Pitx3 activity promotes the survival of SNc mdDA neurons and which factors act upstream and downstream of Pitx3 in this context. Here we show that a transient expression of glial cell line-derived neurotrophic factor (GDNF) in the murine ventral midbrain (VM) induces transcription of Pitx3 via NF-κB-mediated signaling, and that Pitx3 is in turn required for activating the expression of brain-derived neurotrophic factor (BDNF) in a rostrolateral (SNc) mdDA neuron subpopulation during embryogenesis. The loss of BDNF expression correlates with the increased apoptotic cell death of this mdDA neuronal subpopulation in Pitx3(-/-) mice, whereas treatment of VM cell cultures with BDNF augments the survival of the Pitx3(-/-) mdDA neurons. Most importantly, only BDNF but not GDNF protects mdDA neurons against 6-hydroxydopamine-induced cell death in the absence of Pitx3. As the feedforward regulation of GDNF, Pitx3, and BDNF expression also persists in the adult rodent brain, our data suggest that the disruption of the regulatory interaction between these three factors contributes to the loss of mdDA neurons in Pitx3(-/-) mutant mice and perhaps also in human PD.


Subject(s)
Brain-Derived Neurotrophic Factor/biosynthesis , Corpus Striatum/metabolism , Dopamine/physiology , Glial Cell Line-Derived Neurotrophic Factor/pharmacology , Homeodomain Proteins/physiology , Neurons/metabolism , Substantia Nigra/metabolism , Transcription Factors/physiology , Animals , Apoptosis/drug effects , Apoptosis/physiology , Cell Count , Corpus Striatum/cytology , Corpus Striatum/embryology , Female , Hydroxydopamines/toxicity , Immunohistochemistry , In Situ Hybridization , Luciferases/metabolism , Mesencephalon/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Mutation/physiology , NF-kappa B/metabolism , Nerve Growth Factors/pharmacology , Neurons/drug effects , Pregnancy , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction , Substantia Nigra/cytology , Substantia Nigra/embryology , Sympatholytics/toxicity
18.
Neural Dev ; 6: 29, 2011 Jun 20.
Article in English | MEDLINE | ID: mdl-21689430

ABSTRACT

BACKGROUND: The ventral midbrain contains a diverse array of neurons, including dopaminergic neurons of the ventral tegmental area (VTA) and substantia nigra (SN) and neurons of the red nucleus (RN). Dopaminergic and RN neurons have been shown to arise from ventral mesencephalic precursors that express Sonic Hedgehog (Shh). However, Shh expression, which is initially confined to the mesencephalic ventral midline, expands laterally and is then downregulated in the ventral midline. In contrast, expression of the Hedgehog target gene Gli1 initiates in the ventral midline prior to Shh expression, but after the onset of Shh expression it is expressed in precursors lateral to Shh-positive cells. Given these dynamic gene expression patterns, Shh and Gli1 expression could delineate different progenitor populations at distinct embryonic time points. RESULTS: We employed genetic inducible fate mapping (GIFM) to investigate whether precursors that express Shh (Shh-GIFM) or transduce Shh signaling (Gli1-GIFM) at different time points give rise to different ventral midbrain cell types. We find that precursors restricted to the ventral midline are labeled at embryonic day (E)7.5 with Gli1-GIFM, and with Shh-GIFM at E8.5. These precursors give rise to all subtypes of midbrain dopaminergic neurons and the anterior RN. A broader domain of progenitors that includes the ventral midline is marked with Gli1-GIFM at E8.5 and with Shh-GIFM at E9.5; these fate-mapped cells also contribute to all midbrain dopaminergic subtypes and to the entire RN. In contrast, a lateral progenitor domain that is labeled with Gli1-GIFM at E9.5 and with Shh-GIFM at E11.5 has a markedly reduced potential to give rise to the RN and to SN dopaminergic neurons, and preferentially gives rise to the ventral-medial VTA. In addition, cells derived from Shh- and Gli1-expressing progenitors located outside of the ventral midline give rise to astrocytes. CONCLUSIONS: We define a ventral midbrain precursor map based on the timing of Gli1 and Shh expression, and suggest that the diversity of midbrain dopaminergic neurons is at least partially determined during their precursor stage when their medial-lateral position, differential gene expression and the time when they leave the ventricular zone influence their fate decisions.


Subject(s)
Hedgehog Proteins/genetics , Hedgehog Proteins/physiology , Mesencephalon/physiology , Neural Stem Cells/physiology , Signal Transduction/genetics , Signal Transduction/physiology , Animals , Astrocytes/physiology , Brain Mapping , Cell Differentiation/genetics , Dopamine/physiology , Female , Fluorescent Antibody Technique , In Situ Hybridization , Kruppel-Like Transcription Factors/genetics , Kruppel-Like Transcription Factors/physiology , Mesencephalon/cytology , Mesencephalon/embryology , Mice , Neurons/physiology , Oculomotor Nerve/embryology , Oculomotor Nerve/growth & development , Pregnancy , RNA/biosynthesis , RNA/genetics , Red Nucleus/cytology , Red Nucleus/embryology , Red Nucleus/physiology , Substantia Nigra/embryology , Substantia Nigra/growth & development , Substantia Nigra/physiology , Zinc Finger Protein GLI1
19.
Behav Brain Res ; 216(1): 129-35, 2011 Jan 01.
Article in English | MEDLINE | ID: mdl-20655334

ABSTRACT

Many Parkinson's disease (PD) patients suffer from anxiety disorders, which often precede the onset of classical motor symptoms. So far, there is no evidence from randomized, placebo-controlled trials for successful treatment of anxiety in patients with PD. Grafts of fetal nigral neurons are currently explored as a restorative cell therapy for PD. In PD animal models, intrastriatal transplantations of embryonic dopaminergic neurons have been shown to ameliorate behavioral defects. In our previous study we showed that expanded and differentiated neural progenitors improved drug-induced rotation behavior and posture balance as a more complex motor task. However, it is not clear whether grafting of these cells affected spontaneous locomotor activity and anxiety-like behavior in 6-OHDA lesioned rats. Therefore, we analyzed behavior of control, lesioned, sham-transplanted, and transplanted rats using open field (OF) and elevated plus maze (EPM). After unilateral 6-OHDA lesion of the medial forebrain bundle, we observed reduced locomotor activity in the EPM (wall-rearing, entries in closed arms) in lesioned and sham-transplanted rats, which correlated with the loss of dopaminergic neurons and apomorphine-induced rotation behavior. Furthermore, anxiety-like behavior in the EPM (entries and time in open arms) was increased in lesioned and sham-transplanted rats. Although exogenous cell replacement improved apomorphine-induced rotation behavior, locomotor activity and anxiety-like behavior was not reconstituted in transplanted rats. However, we provided evidence for an interaction of locomotor activity/anxiety-like behavior with graft localization in the host striatum. These results emphasize the crucial role of graft localization for benefit of restorative cell therapy for PD.


Subject(s)
Anxiety/physiopathology , Corpus Striatum/transplantation , Dopamine/metabolism , Medial Forebrain Bundle/physiopathology , Motor Activity/physiology , Neurons/transplantation , Substantia Nigra/transplantation , Analysis of Variance , Animals , Brain Tissue Transplantation , Corpus Striatum/embryology , Corpus Striatum/metabolism , Female , Fetal Tissue Transplantation , Immunohistochemistry , Neurons/metabolism , Random Allocation , Rats , Rats, Sprague-Dawley , Substantia Nigra/embryology , Substantia Nigra/metabolism , Tyrosine 3-Monooxygenase/metabolism
20.
Brain Res Bull ; 83(6): 321-30, 2010 Nov 20.
Article in English | MEDLINE | ID: mdl-20884338

ABSTRACT

Glial cell line-derived neurotrophic factor (GDNF) has an essential role in the survival and maturation of the dopaminergic (DA) neurons in the substantia nigra (SN) of mammalian embryonic brain. In addition to Ret, cell adhesion molecules (CAMs) were also proposed to function as transmembrane signaling receptors of GDNF. The present study was to investigate whether these transmembrane receptors of GDNF were correlated with the tyrosine hydroxylase (TH) expression of SN DA neurons during early developmental stage. RT-PCR and Western blot were performed to detect TH expression in SN of perinatal rats at mRNA and protein level respectively; meanwhile, Western blot was performed to detect the expressions of the transmembrane proteins including Ret, neural cell adhesion molecule-140 (NCAM-140), integrin ß1 and N-cadherin. The results showed that TH mRNA expression was positively correlated with both Ret and N-cadherin protein, while there was no correlation with NCAM-140 and integrin ß1; TH protein expression was correlated with all of these transmembrane molecules. These data suggested that the expression of either TH mRNA or TH protein was subject to the mediation of different transmembrane receptor combinations of GDNF.


Subject(s)
Gene Expression Regulation, Developmental/physiology , Glial Cell Line-Derived Neurotrophic Factor Receptors/metabolism , Neurons/metabolism , Substantia Nigra , Tyrosine 3-Monooxygenase/metabolism , Age Factors , Analysis of Variance , Animals , Animals, Newborn , Cadherins/metabolism , Cell Adhesion Molecules, Neuronal/metabolism , Cell Count/methods , Embryo, Mammalian , Glial Cell Line-Derived Neurotrophic Factor Receptors/genetics , Integrin beta1/metabolism , Proto-Oncogene Proteins c-ret/metabolism , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Statistics as Topic , Substantia Nigra/cytology , Substantia Nigra/embryology , Substantia Nigra/growth & development , Tyrosine 3-Monooxygenase/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...